Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma

NCT04990778 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped PI Request

Conditions

Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma

Interventions

DRUG: Eprenetapopt
DRUG: Venetoclax

Sponsor

M.D. Anderson Cancer Center